10-Q: BioSig Technologies Reports Q2 2024 Results Amidst Delisting and Restructuring
Sentiment:
Quarterly Report
BioSig Technologies reports a net loss of $7.455 million for the six months ended June 30, 2024, while navigating delisting from Nasdaq and significant operational changes.
Capital raiseThe company sold an aggregate of 260,720 shares of common stock and warrants for gross proceeds of $1,040,000 on January 12, 2024.On May 1, 2024, the company sold 783,406 shares of common stock and warrants for aggregate consideration of $1,144,164, including $634,999 in cash and $509,165 representing conversion of a related party note.On May 29, 2024, the company agreed to sell 1,570,683 shares of common stock and warrants for gross proceeds of approximately $3.0 million.
Worse than expectedThe company's net loss, while reduced year-over-year, is still substantial and indicates ongoing financial challenges.The delisting from Nasdaq is a significant negative event that reflects the company's failure to meet listing requirements.The workforce reduction and resignations of key personnel suggest operational instability and potential challenges in executing the company's strategy.
Summary
- BioSig Technologies reported a net loss attributable to common shareholders of $7.455 million for the six months ended June 30, 2024, compared to a net loss of $18.430 million for the same period in 2023.
- The company's revenue for the first half of 2024 was $27, a significant increase from $5 in the first half of 2023.
- Operating expenses decreased to $8.756 million for the first six months of 2024, down from $18.299 million in the same period of 2023.
- Research and development expenses decreased to $580,000 for the first six months of 2024, compared to $2.771 million in the same period of 2023.
- General and administrative expenses also decreased to $7.796 million for the first six months of 2024, down from $15.352 million in the same period of 2023.
- The company experienced a gain on settlement and forgiveness of accounts payable of $1.388 million.
- BioSig Technologies faced delisting from Nasdaq due to non-compliance with minimum stockholders' equity requirements, and its stock now trades on the OTCQB.
- The company underwent a significant workforce reduction, impacting operations and leading to resignations of board members and officers.
- BioSig Technologies is exploring strategic partnerships and commercialization of its PURE EP System to improve its financial position.
Sentiment
Score: 3
Explanation: The document reveals significant financial challenges, including substantial losses, delisting from Nasdaq, and a workforce reduction. While there are some positive signs like reduced operating expenses and increased revenue, the overall sentiment is negative due to the company's precarious financial position and operational instability.
Positives
- The company's net loss decreased significantly year-over-year, indicating improved financial performance.
- Revenue increased substantially, although from a very low base, suggesting potential for future growth.
- Operating expenses were significantly reduced, demonstrating cost-cutting measures.
- The company achieved a gain from the settlement and forgiveness of accounts payable, improving its financial position.
- BioSig Technologies is actively seeking strategic partnerships and commercialization opportunities.
Negatives
- The company experienced a net loss of $7.455 million for the first half of 2024.
- BioSig Technologies was delisted from Nasdaq due to non-compliance with minimum stockholders' equity requirements.
- The company underwent a significant workforce reduction, which may impact operations.
- There were resignations of key board members and officers, indicating instability.
- The company has a working capital deficit of $0.6 million as of June 30, 2024.
Risks
- The company's ability to continue as a going concern is in doubt due to net losses and negative cash flows.
- BioSig Technologies faces challenges in generating sufficient cash flow to fund operations.
- The company's research and development efforts may not be successful or commercially viable.
- The company's stock is now subject to the penny stock rules, which may limit trading activity.
- The company is subject to legal proceedings and claims, which could have a material adverse effect on its financial position.
- The company has identified material weaknesses in its internal control over financial reporting.
Future Outlook
The company plans to continue commercializing the PURE EP System, explore strategic partnerships, and raise capital through the sale of additional equity securities or debt. They also intend to hire a team to execute a business development strategy and develop new products in the field of Pulse Field Ablation.
Management Comments
- Management of the Company commenced a workforce reduction intended to reduce significantly the annual cash burn.
- The effect of the workforce reductions has significantly reduced operations in the short term.
- The Company will require additional financing to fund future operations.
- The Company's strategic shift to potentially hiring a team of an additional 4-6 persons to execute a business development strategy of finding partners for the commercialization of PURE EP, develop new products in the field of Pulse Field Ablation and to continue to integrate PURE EP into todays lab equipment will allow the Company to significantly reduce operating expenses.
Industry Context
The medical device industry is highly competitive, and BioSig Technologies faces challenges in commercializing its PURE EP System. The company's focus on electrophysiology and cardiac arrhythmias aligns with the growing need for advanced diagnostic and treatment solutions in this area. The delisting from Nasdaq and subsequent trading on the OTCQB reflects the company's financial struggles and the need for strategic changes to regain investor confidence.
Comparison to Industry Standards
- BioSig's revenue of $27,000 for the first half of 2024 is significantly lower than established medical device companies, which often report revenues in the millions or billions.
- The company's net loss of $7.455 million for the first half of 2024 is substantial, indicating a need for significant improvement in profitability.
- Compared to companies like Boston Scientific or Medtronic, which have established market presence and diverse product portfolios, BioSig is still in an early commercialization stage.
- The workforce reduction and delisting from Nasdaq are not typical for established medical device companies, highlighting the challenges BioSig is facing.
- The company's focus on strategic partnerships and commercialization is a common strategy for smaller medical device companies seeking to expand their market reach.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Financial Officer | Steve Buhaly | Ferdinand Groenewald (Acting) | 2024-06-05 | Resignation of previous CFO |
| Director | David Weild IV, Donald E. Foley, Patrick J. Gallagher, James J. Barry, James L. Klein, Frederick D. Hrkac | Chris Baer, Steven E. Abelman, Donald F. Browne | 2024-02-19, 2024-02-20, 2024-05-02, 2024-05-03 | Resignations of previous directors |
| President and Principal Executive Officer | Kenneth L. Londoner | Anthony Amato | 2024-04-30 | Resignation of previous CEO |
| President and Principal Executive Officer | Frederick D. Hrkac | Anthony Amato | 2024-04-30 | Appointment of new CEO |
| Acting Chief Financial Officer | Frederick D. Hrkac | Ferdinand Groenewald | 2024-06-05 | Resignation of previous acting CFO |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Delisting from Nasdaq | The company's common stock was delisted from Nasdaq due to non-compliance with minimum stockholders' equity requirements. | 2024-06-12 | Negative impact on investor confidence and stock price. |
| Trading on OTCQB | The company's common stock began trading on the OTCQB. | 2024-07-23 | Reduced visibility and liquidity compared to Nasdaq. |
Legal Proceedings
- The company received a threat of litigation for the termination of employment, alleging retaliation for bringing wrongful practices to the attention of the board.
- The company received a threat of litigation seeking restitution for losses resulting from unlawful actions taken by the board of directors.
- Michael Gray Fleming filed a lawsuit against the company, alleging failure to meet obligations in issuing stock certificates under a restricted stock award agreement.
Related Party Transactions
- The company issued a promissory note for $500,000 to a significant shareholder/investor.
- The company converted the promissory note and related accrued interest into shares of common stock and warrants.
- Accounts payable and accrued expenses include amounts due to related parties, primarily director fees and travel reimbursements.
- The company issued shares of common stock to Frederick D Hrkac and Anthony Amato in exchange for consulting services.
Stakeholder Impact
- Shareholders have experienced a significant decrease in the value of their investment due to the delisting from Nasdaq and the company's financial struggles.
- Employees have been impacted by the workforce reduction, leading to job losses and uncertainty.
- Customers may experience disruptions in service due to the company's operational changes.
- Suppliers and creditors may face increased risk due to the company's financial instability.
- The company's ability to attract future investment and partnerships may be negatively affected by its current situation.
Next Steps
- The company intends to continue commercializing the PURE EP System.
- BioSig Technologies will explore strategic partnerships.
- The company plans to raise capital through the sale of additional equity securities or debt.
- BioSig Technologies intends to hire a team to execute a business development strategy and develop new products in the field of Pulse Field Ablation.
- The company is awaiting a decision on its appeal to the Nasdaq Listing and Hearing Review Council.
Key Dates
| Date | Description |
|---|---|
| 2017-03-15 | BioSig entered into a know-how license agreement with Mayo Foundation. |
| 2019-09-24 | ViralClear's Board of Directors approved the 2019 Long-Term Incentive Plan. |
| 2019-11-20 | BioSig entered into a patent and know-how license agreement (the EP Software Agreement) with Mayo Foundation. |
| 2023-06-17 | BioSig AI entered into a consulting agreement with Reified Labs LLC. |
| 2023-12-04 | BioSig received a threat of litigation for termination of employment. |
| 2024-01-28 | Management commenced a workforce reduction. |
| 2024-01-31 | The Company filed a Reverse Stock Split Amendment. |
| 2024-02-15 | Steve Buhaly resigned from his position as the Chief Financial Officer. |
| 2024-02-19 | David Weild IV, Donald E. Foley, Patrick J. Gallagher and James J. Barry, resigned from their positions as directors. |
| 2024-02-20 | James L. Klein and Frederick D. Hrkac resigned from their positions as directors. |
| 2024-02-20 | The workforce reduction was completed. |
| 2024-02-22 | BioSig received a threat of litigation seeking restitution for losses. |
| 2024-02-27 | Frederick D. Hrkac was re-appointed as a director and the president and principal executive officer. |
| 2024-02-27 | Kenneth L. Londoner resigned from his positions as director, executive chairman and chief executive officer. |
| 2024-03-05 | BioSig received a letter from Nasdaq stating it has not regained compliance with Listing Rule 5550(a)(2). |
| 2024-03-07 | BioSig issued a promissory note for $500,000 to a significant shareholder/investor. |
| 2024-03-11 | BioSig submitted a request for a hearing before the Nasdaq Hearings Panel. |
| 2024-03-12 | BioSig received a letter from Nasdaq stating it no longer has an operating business. |
| 2024-03-22 | Michael Gray Fleming filed a lawsuit against BioSig. |
| 2024-04-30 | Anthony Amato was appointed as a director, president, chief executive officer and principal executive officer. |
| 2024-05-01 | BioSig entered into a securities purchase agreement with certain accredited investors. |
| 2024-05-02 | Chris Baer was appointed as a director on the Board. |
| 2024-05-03 | Steven E. Abelman and Donald F. Browne were appointed as directors on the board. |
| 2024-05-29 | BioSig entered into a securities purchase agreement with certain institutional investors. |
| 2024-06-05 | Frederick D. Hrkac resigned as acting chief financial officer and principal accounting officer. |
| 2024-06-05 | BioSig and Ferdinand Groenewald entered into a consulting agreement. |
| 2024-06-07 | The Company granted an aggregate of 262,500 restricted stock units for shares of its common stock to employees and board members. |
| 2024-06-10 | BioSig received formal notice that the Nasdaq Hearings Panel had determined to delist the Companys common stock. |
| 2024-06-12 | Trading in BioSig's securities was suspended on Nasdaq. |
| 2024-06-24 | BioSig was notified by Nasdaq that the Nasdaq Hearings Panel had declined to reconsider its decision to delist the Companys common stock. |
| 2024-07-01 | BioSig announced the intent to acquire the assets of Neuro-Kinesis Corporation. |
| 2024-07-08 | The Company terminated a lease for $60,000. |
| 2024-07-10 | BioSig filed a submission in support of an appeal to the Delisting Decision to the Nasdaq Listing and Hearing Review Council. |
| 2024-07-15 | The Company terminated its sublease for the office space at 55 Greens Farms Road Westport, Connecticut. |
| 2024-07-23 | BioSig commenced trading of its common stock on the OTCQB. |
| 2024-07-26 | The Company issued 280,000 shares of its common stock to board members, employees and a consultant for services rendered. |
| 2024-07-26 | The Company paid $25,000 in cash and issued 112,500 shares of its common stock as a full settlement of the General Release and Severance Agreement. |
| 2024-08-01 | The Company issued 62,500 shares of its common stock for vested restricted stock units. |
Keywords
BioSig Technologies, PURE EP System, electrophysiology, delisting, workforce reduction, financial results, net loss, revenue, operating expenses, strategic partnerships, OTCQB, stock warrants, stock options, medical device
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.